ArticleInternational journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group2026
Feasibility of thermal dose painting during magnetic nanoparticle thermal therapy: a computational analysis.
Article in International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Verification and validation in canine cadaver of an MPI-integrable RF head coil for magnetic particle hyperthermia.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026Article
- Design, verification and validation of a spatially confined magnetic nanoparticle thermal therapy device for conformal thermal dose contouring.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSpatially confined magnetic nanoparticle thermal therapy (SC-MNTT) can improve the tumor coverage index (CI) when the magnetic field-free region (FFR) is manually steered. However, static steering demands significant time and expertise from experienced control engineers during treatment planning.
objectiveThis study presents a computational framework for automated, dynamic FFR steering combined with real-time tumor boundary temperature control to enhance magnetic nanoparticle thermal therapy (MNTT) for cancer therapy. The framework also supports controlled MNTT treatment planning.
methodWe integrated the Pennes bioheat transfer equation with a proportional-integral-derivative (PID) controller to maintain the maximum tumor boundary temperature at 46 °C. The magnetic nanoparticle (MNP) heat source was divided into four subdomains to simulate SC-MNTT. A fuzzy logic controller automatically selected the FFR based on four-point temperature measurements and corresponding thermal dose, aiming to maximize CI. We examined the influence of key treatment parameters: maximum treatment temperature (60 or 80 °C), MNP distribution (uniform or Gaussian), sensor noise, and MNP position relative to the tumor center.
resultsAutomated dynamic FFR steering increased CI by ∼25-35%, depending on these parameters. The highest CI occurred at a maximum treatment temperature of 80 °C with a uniform MNP distribution. Sensor noise had minimal effect, while minimal offset between the MNP position and tumor center was essential for maximizing CI.
conclusionThe proposed fuzzy logic-based dynamic FFR steering may reduce reliance on expert control engineers for SC-MNTT treatment planning. Future work will focus on pre-clinical implementation and experimental validation of the control system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.